Abstract
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.
Original language | English (US) |
---|---|
Pages (from-to) | 307-310 |
Number of pages | 4 |
Journal | Pediatric Blood and Cancer |
Volume | 54 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2010 |
Externally published | Yes |
Keywords
- Developmental therapeutics
- Mapatumumab
- Preclinical testing
ASJC Scopus subject areas
- Hematology
- Oncology
- Pediatrics, Perinatology, and Child Health